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Objective To analyze the clinical and laboratory features of patients diagnosed with
streptococcal toxic shock syndrome (TSS) in North Yorkshire from 1986 to 1999.
Methods Records of patients with features satisfying the published criteria for strepto-
coccal TSS were reviewed from laboratory and clinical records made at the time and from
the hospital case notes. Isolates of streptococci were analyzed for serotype and genes
encoding for the production of streptococcal pyrogenic exotoxins.
Results Fourteen patients satisfied the entry criteria. In one district, where the data were
complete, the annual incidence of detected streptococcal TSS rose from 1.1 to 9.5 cases per
million population in the 1990s. TSS was associated with various M serotypes of group A
streptococci and various exotoxin genotypes. Two cases (14% of the series) were
associated with severe group G streptococcal infection. The fatality rate was 64%, and
the mode of time to death was 4 days. Local tissue necrosis occurred in 71% of cases,
including necrotizing fasciitis, intrathoracic and intra-abdominal forms. Non-steroidal
anti-inflammatory drugs (NSAIDs) had been taken around the time of onset of disease by
92% of the patients with TSS.
Conclusions There has been a dramatic increase in the number of detected cases of
streptococcal TSS over the 14 years since the first case was recognized here. There was a
wide range of invasive forms of infection, a high fatality rate even in fit young adults, and
a rapid course from onset to death. There was a high association of TSS with aggressive
streptococcal infection producing local tissue necrosis.
Keywords Toxic shock syndrome, group A streptococcus, Streptococcus pyogenes, group
G streptococcus, non-steroidal anti-inflammatory drugs, necrotizing fasciitis
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I N T R O D U C T I O N
There has been a general resurgence of serious
forms of Streptococcus pyogenes infection in many
parts of the developed world during the last
15 years, and a newly recognized streptococcal
‘toxic shock syndrome’ (TSS) has been described
during this period [1–3]. The generally accepted
case definition for group A streptococcal TSS [4]
specifies isolation of the organism, substantial
hypotension and two or more of the following
features: renal or hepatic failure, coagulopathy,
adult respiratory distress syndrome, generalized
rash and soft tissue necrosis. It is likely that TSS is
the counterpart of the malignant and toxic forms of
serious streptococcal infection (such as in scarlet
fever) that were reported by clinicians in the pre-
antibiotic era [5]. The occurrence of streptococcal
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TSS in the UK has been noted in case reports and in
the recent 3-year PHLS prospective study of ser-
ious S. pyogenes infections [6] but, to date, there has
been no specific description of the disease as it
occurs in this country. We present an analysis of
the clinical and laboratory features of patients
diagnosed with streptococcal TSS in North York-
shire from 1986 to 1999.
M A T E R I A L S A N D M E T H O D S
Records of all detected serious infections with
hemolytic pyogenic streptococci (invasive, bac-
teremic or toxic) in the Harrogate district of North
Yorkshire, population 150 000, have been saved for
the last 20 years. Patients yielding pyogenic strep-
tococci and showing features satisfying the pub-
lished clinical criteria for streptococcal TSS [4]
were reviewed from laboratory and clinical
records made at the time and from the hospital
case notes. Two recent additional cases from the
York district and one from the Northallerton dis-
trict are included in the review. Clinical isolates of
streptococci were identified by standard labora-
tory methods [7], including Lancefield grouping
by latex agglutination techniques and disk diffu-
sion antibiotic susceptibility testing in the York-
shire laboratories. They were analyzed by one of
us for M-protein and T-antigen serotype [7] and
for genes encoding for the production of strepto-
coccal pyrogenic exotoxins A–C [8] at the Respira-
tory and Systemic Infection Laboratory, Central
Public Health Laboratory, Colindale.
R E S U L T S
Details of 14 patients in a 14-year period (1986,
when the first case was recognized here, to 1999)
who developed serious streptococcal infection
complicated by TSS are shown in Table 1. Twelve
patients were infected with S. pyogenes and two
with group G streptococci (large colony, S. dysga-
lactiae subspecies equisimilis). The patients were
aged 30–86 years, mean 59 years, and nine (64%)
were males. Portals of entry of infection were
unknown in most cases but included the skin (cuts
and burns in three patients) and the genital tract at
parturition (in one). Overall, nine of 14 patients
(64%) died, including three of five (60%) in the age
group 30–40 years and six of nine (67%) aged more
than 60 years. The time elapsing from clinical onset
of infection with S. pyogenes to death ranged from 2
to 9 days, with a mode of 4 days. Nine of the
infections (64%) occurred in the winter months
October to March. The annual incidence of
detected streptococcal TSS in the Harrogate dis-
trict increased during the study from 1.1 (one case
in the first 6 years) to 9.5 cases (10 in the subse-
quent 7 years) per million population. Features of
the infections are shown in Table 2, and possible
predisposing factors in Table 3. The appearances
of two patients with TSS are shown in Figure 1.
Treatment of the patients (Table 1) included anti-
biotics, supportive management in the intensive
care unit in ten cases (71%, others being deemed
unsuitable on account of late presentation, age and
clinical condition) and surgery in six cases (43%),
including debridement, excisions of necrotic tis-
sue, amputation (in one case), laparotomy, bowel
resection (in one case), splenectomy, placement of
drains and skin grafting in convalescence. Details
of the serotyping and genotyping of S. pyogenes
case isolates are shown in Table 4. The isolates
were not tested for production of pyrogenic exo-
toxins. All isolates of S. pyogenes tested were sus-
ceptible to penicillin and erythromycin, but two of
ten (20%) were resistant to tetracycline.
D I S C U S S I O N
This appears to be the first account from the UK
describing a series of patients with streptococcal
TSS; we have reported individual features of some
of the cases in previous presentations and pub-
lications [9–15]. We have saved details of patients
with severe streptococcal infections over a 20-year
period and believe that the striking increase in
detected TSS in this locality during the 1990s is
a real phenomenon, consistent with the general
resurgence that has been noted by others [2,5].
The patients suffered a wide range of invasive
forms of infection, but the occurrence of detected
bacteremia in 86% and local tissue necrosis in 71%
of cases was notable. Intra-abdominal forms of
streptococcal infection with TSS have been
described only rarely; three of our patients
(21%) featured peritonitis, including one with
necrosis of the omentum and splenic infarction,
and one with necrotizing proctitis that required
surgical excision [10]. Surgery is a particularly
important element in the treatment of patients
with severe local streptococcal infection [16] and
was employed in our series in nearly one half of
the patients; some others were too unwell or died
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Table 1 Details of 14 patients with streptococcal TSS
Case
no.
Date
(month/
year)
Patient’s
age
(year)
Strepto-
coccus
group
serotype
Site(s) of
isolation
NSAIDs
taken
around
onset
Clinical
features
Anemia,
leuco-
cytosis
Leucopenia
lympho-
penia
ICU,
surgery
employed
IVIG,
antibiotics
employed Outcome
Time from
onset to
death (days)
1 8/86 39 A, T1M1 Blood,
knee
aspirate
NK Septic
arthritis knee,
NF leg ARF,
LFT deranged
, þ , NT þ,  , pen Died 2
2 1/93 78 A, T28R28 Blood Fenbufen Infected
THR, ARF,
LFT deranged
þ, þ , þ þ,  , flu Died 4
3 3/93 75 A, T12M12 Blood No Diffuse
septicemia,
ARF, DIC,
ARDS, rash,
jaundice,
shingles
þ, þ , þ þ,  , pen,
ctx, clind
Survived
4 10/94 40 A, T3M3 Blood Diclofenac Cellulitis
from burn on
hand NF
shoulder, ARF,
DIC, rash,
pleural
effusion,
LFT deranged
þ,  þ, þ þ,  þ, pen, ctx,
clind, metro
Died 3
5 12/95 33 A, T1M1 Blood,
perineal
tissue
Diclofenac Postpartum
NF perineum,
peritonitis
DIC,
LFT deranged
þ, þ þ, þ þ, þ , aug, gent,
clind, metro
Survived
6 12/95 30 A, T1M1 Blood,
sputum
Ibuprofen Necrotizing
pneumonia, fits,
pleural effusion,
ARF, DIC
, - , þ þ, þ , ctx, metro Died 4
7 1/96 86 A, T1M1 Blood Diclofenac NF arm,
myonecrosis,
ARF, DIC
þ, þ þ, þ ,  , pen, clind Died 9
8 5/96 34 A, T3M3 Knee
bursa
pus
Aspirin Septic arthritis
knee, NF leg
ARF, DIC rash
,  , þ þ, þ , pen, ctx,
clind
Survived
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Table 1 continud
Case
no.
Date
(month/
year)
Patient’s
age
(year)
Strepto-
coccus
group
serotype
Site(s) of
isolation
NSAIDs
taken
around
onset
Clinical
features
Anemia,
leuco-
cytosis
Leucopenia
lympho-
penia
ICU,
surgery
employed
IVIG,
antibiotics
employed Outcome
Time from
onset to
death (days)
9 5/97 72 A, T4M4 Blood, PM:
leg tissues,
kidney
Aspirin NF leg, myone-
crosis ARF,
multiorgan
failure
NT NT ,  ,  Died 3
10 9/98 67 A, T5M5 Arm pus NK NF hand
and arm,
ARF, ARDS
þ,  , þ þ, þ , pen, clind,
metro
Died 3
11 1/99 62 A, T6M6 Blood Aspirin Septic arthritis
wrist, ARF,
DIC, ARDS,
LFT deranged
þ, þ , þ ,  , pen, flu,
teico
Died 4
12 5/99 65 A, T28R28 Blood,
wound,
peritoneal
pus
Ibuprofen Necrotizing
proctitis, ARF,
peritonitis,
LFT deranged
þ, þ , þ þ, þ , pen, ctx,
clind, metro,
pip/taz
Survived
13 2/94 67 G Blood,
spleen
Ibuprofen Peritonitis,
omental
necrosis, splenic
infarct, DIC,
LFT deranged
þ, þ , þ þ, þ , pen, ctx,
clind, metro
Died 31
14 11/94 83 G Blood Diclofenac Ulcerating
cellulitis leg
and thigh, ARF,
DIC, rash
þ, þ , þ ,  , pen, flu,
ctx, gent
Survived
Antibiotics: aug, co-amoxiclav; clind, clindamycin; ctx, cefotaxime; flu, flucloxacillin; gent, gentamicin; metro, metronidazole; pen, penicillin G; pip/taz, piperacillin plus
tazobactam; teic, teicoplanin; ARDS, adult respiratory distress syndrome; ARF, acute renal failure; DIC, disseminated intravascular coagulation; ICU, intensive care unit;
IVIG, intravenous pooled immunoglobulin; LFT, liver function tests; NF, necrotizing fasciitis; NK, not known; NSAIDs, non-steroidal anti-inflammatory drugs taken
around onset of infection; NT, not tested; THR, total hip replacement. Hematologic parameters as defined in Table 2. Note: all patients had hypotension/shock.
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Table 2 Frequency of clinical and laboratory features in 14
patients with TSS
Feature
No. (%) of patients
showing feature
Hypotension 14 (100%)
Acute renal failure 13 (93%)
Necrotic infection 10 (71%)
Necrotizing fasciitis 7
Myonecrosis (with NF) 2
Necrotizing pneumonia 1
Necrotizing proctitis 1
Omental necrosis 1
Disseminated intravascular
coagulation
9 (64%)
Fatality 9 (64%)
Deranged liver function 8 (57%)
Multiorgan failure 6 (43%)
Extensive surgery employed 5 (36%)
Septic arthritis 4 (29%)
Generalized rash 4 (29%)
Adult respiratory distress
syndrome
3 (21%)
Peritonitis 3 (21%)
Cellulitis 2 (14%)
Diffuse septicemia 1 (7%)
Detected bacteremia 12 (86%)
Lymphopenia 12/12 Tested (100%)
Anemia 10/13 Tested (77%)
Leucocytosis 9/13 Tested (69%)
Leucopenia 3/13 Tested (23%)
NF, necrotizing fasciitis.
Anemia¼<12 g/dL hemoglobin.
Leucocytosis¼>10 109/L.
Leucopenia¼<3.6 109/L. Lymphopenia¼<1.0 109/L.
NB. Listed features are not mutually exclusive.
Table 3 Premorbid, potential predisposing factors in 14
patients with TSS
Factor
No. of patients (%)
with factor
NSAIDsa 11/12 Questioned about the
drugs (92%)
No factors listed below 4 (29%)
Osteoarthritis 3 (21%)
Alcoholism 2 (14%)
Obesity 2 (14%)
Early postoperative periodb 1 (7%)
Early postpartum period 1 Featuring genital tract and
perineal necrosis (7%)
Heavy smoking 1 Featuring pneumonia (7%)
Gout 1 (7%)
aNon-steroidal anti-inflammatory drugs taken just before
or around onset of infection.
bTransurethral prostatectomy followed by diffuse septice-
mia. NB. Listed factors are not mutually exclusive.
Figure 1 (a) Case no. 4: profound intoxication in a patient
with ascending S. pyogenes serotype T3M3 infection aris-
ing from a small burn on the hand acquired while cooking;
the bruised appearance in the area of the right clavicle
heralds impending necrotizing fasciitis. (b) Case no. 9:
appearances of necrotizing fasciitis and extensive myone-
crosis in the thigh at autopsy in a patient with intoxicating
and rapidly fatal S. pyogenes serotype T4M4 infection
arising from a pretibial laceration after stumbling in the
street.
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too quickly to undergo surgery. Supportive ther-
apy in an intensive care unit setting was used for
most patients, and multiple antibiotics were
usually employed (Table 1), but there were insuf-
ficient data to judge the merits of particular regi-
mens in our patients. Intravenous gamma-
globulin therapy, intended to neutralize strepto-
coccal toxins, has been advocated recently but
remains controversial [17–19]; it was used in only
one patient in our series, who unfortunately died.
Infections were caused by a variety of serotypes
of S. pyogenes, but strains of M-types 1 and 3
accounted for 50% of cases. Others have noted
the association of these types with TSS [2,20–24],
and it is thought that there has been a worldwide
spread of certain clones with the ability to produce
pyrogenic exotoxins (SPEs, or scarlet fever toxins)
responsible for the intoxicating forms of disease
[21]. SPEs function as superantigens to produce
widespread recruitment of immunocompetent
cells, derangement of cytokine production and
profound disturbances in body function [25–29];
depletion of circulating lymphocytes may be part
of this process [30] and was a universal finding in
our patients. The known range of SPEs is expand-
ing in the light of modern research [31], and it is
presently unclear which are the most important in
the pathogenesis of TSS. Host and environmental
factors are thought also to be important in the
etiology of the disease [22,31,32]. The genes for
toxins A–C identified in the serotypes of S. pyo-
genes found in this study were consistent with
previous findings in strains from a variety of
simple and serious infections in the UK. Genes
encoding for toxin B are almost always present in
S. pyogenes, and our results show that TSS here is
not limited to infection with strains encoding for
one particular toxin, A or C. The isolates were not
tested for expression of the toxin genes, or for the
production of other common factors that might
have been responsible for the serious disease in the
patients.
With the resurgence of serious forms of group A
streptococcal infection noted in many parts of the
world from the mid-1980s to late 1980s
[2,5,6,20,21], cases of TSS have been reported from
many centers in Europe where there is a special
interest in streptococcal infection, including
laboratories in Sweden [22,24], Norway [33], Ger-
many [34], the UK [6], France [35] and Italy [36]. It
may be assumed that such cases have occurred
throughout the continent. Early reports in Europe
[22,24,33] were associated with transient peaks of
invasive S. pyogenes serotype M1 infection and,
although strains of this type, together with sero-
types M3, M12 and R28, have remained frequent
[6,24,36] (as in this report), a variety of other
serotypes has also been encountered in patients
with TSS in most centers. Isolates of serotypes M1
and M3 very often carry the genes for toxin A
[34,35], but SPE gene findings have been variable
in strains of other serotypes [8,24,34]. Studies of
Swedish patients with serious streptococcal infec-
tion in the late 1980s [22] showed a predominance
of isolates producing high amounts of toxin B or
toxin C, and it was concluded that there was no
direct correlation between the A–C toxin profiles
and the outcome of infection.
There was a high mortality rate in our patients,
both in the elderly and in some younger and
previously fit adults, as described by others in
cases of TSS [2,30]. Recent evidence suggests that,
in such patients, lack of circulating antibody to the
infecting serotype and to the relevant SPE corre-
lates with susceptibility to TSS [22–24]. Non-ster-
oidal anti-inflammatory drugs (NSAIDs) are
thought to predispose to severe forms of strepto-
coccal infection and TSS by the immune depres-
sion they cause and by enhancement of cytokine
production on challenge by SPEs [37,38]; although
our study was observational and not designed to
assess any cause and effect in this matter, we did
note a very high incidence of patients taking
NSAIDs.
Two of the 14 cases of TSS in our series (14%)
were associated with infection with group G strep-
tococci, as described only very rarely before [39–
41], and we have seen one further case in the
period following this study; these strains will be
the subject of further analysis. Infection with
Table 4 Features of 12 case isolates of S. pyogenes from
patients with TSS
Serotype
No. of
isolates
No. (%) of
fatal infections
Genes of
toxins present
T1M1 4 3/4 (75%) AB, AB, BC
T3M3 2 1/2 (50%) AB, AB
T4M4 1 1 (100%) AB
T5M5 1 1 (100%) ABC
T6M6 1 1 (100%) B
T12M12 1 0 (0%) BC
T28R28 2 1/2 (50%) BC, BC
Total of all 12 8/12 (67%) 11 Tested
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 174–181
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group G streptococci was not included in the
original working definition of streptococcal TSS
[4]. However, we believe that they should now be
regarded as a potential cause of streptococcal TSS,
in view of our own experience, the case reports by
others, the finding that the organisms can elabo-
rate mitogenic factors [42] and the similar disease
recently described in group G streptococcus-
infected dogs [43].
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